Echo IQ (EIQ) Q1 2026 TU earnings summary

Executive summary

• Achieved key milestones in US commercialisation strategy for EchoSolv, including clinical validation study with Mayo Clinic Platform, advancing toward FDA submission for EchoSolv HF.

• Expanded US market reach through new partnerships, notably with SARC MedIQ and Sclmage, and increased hospital integrations.

• Appointed two leading US cardiologists as strategic advisors to support regulatory and commercial expansion.

• Progressed negotiations for European distribution and CE Mark regulatory engagement.

Financial highlights

• Net cash used in operating activities for the quarter was $2.51 million.

• Cash and cash equivalents at quarter end totaled $15.9 million, down from $18.1 million at the start of the quarter.

• Raised $300,000 from equity securities during the quarter.

• Payments to related parties during the quarter amounted to $165,000.

Outlook and guidance

• Anticipates completion of Mayo Clinic validation study and FDA submission for EchoSolv HF in the next quarter.

• Plans to advance reimbursement strategy for EchoSolv HF using existing CPT codes and expand US and EU market presence.

• Focused on converting US hospital pipeline and integrating with SARC MedIQ’s network.